TrialBreast cancer research : BCR2013

Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

Alison F Munro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.